ChemGenex raises $12.9m
Wednesday, 17 September, 2008
ChemGenex [ASX: CXS] has completed a $12.9 million capital raising through a share placement to institutional investors.
15.2 million shares were sold at $0.85 per share. Over half of these shares were purchased by existing major ChemGenex shareholders.
The company is also offering existing Australian shareholders the ability to participate on the same terms.
Existing major shareholders Alta Partners, GBS Venture Partners and Merck Snate committed $6.5 million.
The funds will be used for ChemGenex’s clinical trial program of its lead drug candidate, omacetaxine, for chronic myeloid leukaemia.
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
